CN107050421A - Purposes of the N15 polypeptides in fungistat is prepared - Google Patents
Purposes of the N15 polypeptides in fungistat is prepared Download PDFInfo
- Publication number
- CN107050421A CN107050421A CN201611168581.5A CN201611168581A CN107050421A CN 107050421 A CN107050421 A CN 107050421A CN 201611168581 A CN201611168581 A CN 201611168581A CN 107050421 A CN107050421 A CN 107050421A
- Authority
- CN
- China
- Prior art keywords
- polypeptides
- prepared
- fungistat
- purposes
- biological function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses purposes of the N15 polypeptides in fungistat is prepared, N15 polypeptides, which are one, has the small peptide of 15 amino acid, it has various biological function, ability including adjusting NF κ B transcription factor binding purpose genes, influences the transcript and expression of NF κ B target gene product albumen matter；PCNA combination archaeal dna polymerases are blocked, so as to prevent cell DNA synthesis from suppressing cell propagation；Suppress epithelial hyperplasia, regulation epidermal hyperplasia and differentiation, make Keratoderma process normalization etc., disclosure sets forth its new biological function, with preferable practicality and industrialization prospect.
Description
Technical field
The present invention relates to biological technical field, purposes of the N15 polypeptides in fungistat is prepared is referred specifically to.
Background technology
Fungi can cause the multiple diseases of animals and plants, not only influence crop yield, economic animal growth production, cause pole
Big economic loss, and influence health, threaten human life's safety.In order to suppress and eliminate disease fungus, Ren Menyi
Directly it is directed to finding effective antifungal drug.Trichophyton rubrum is a kind under trichophyton.Trichophyton rubrum is a kind of
The dermatophytes in people source, causes common pathogenic fungi of superficial mycosis, such as tinea manuum, tinea pedis, favus of the scalp.In the late two decades, by skin tinea
Bacterium and other fungus-caused infection showed increaseds.Have now been found that more than 40 kind dermatophytes mainly have Trichophyton rubrum, palpus
Tinea trichophyta, microsporum canis etc..Trichophyton rubrum (Trichophyton rubrum) belongs to mitosporic fungi,
The therapeutic dermatophyte of ichangjiande relatives property.It is also a kind of most common dermatophyte of China for worldwide distribution.
Saccharomycete is a relatively representational class in fungi, and it is sac fungus, basidiomycetes Deng Ji sections unicellular fungi
Common name, available for production is brewageed, have for pathogenic bacteria.Saccharomycete is that (fungi is naturally present within body to some kinds of fungi
Within).But fungi excessively will also result in problem in vivo, yeast infection may occur at any position of body, mainly
It is, because patient's hypoimmunity, to cause internal flora unbalance caused, itch, cusalgia are the cardinal symptoms of yeast infection.
The content of the invention
It is an object of the invention to provide a kind of polypeptide, the polypeptide can suppress a variety of fungies, including Yeast Growth, tool
There is the purposes in fungistat is prepared, it is disclosed by prior art, entitled N15 polypeptides.
N15 polypeptides, which are one, has the small peptide of 15 amino acid, and its sequence is Met-Pro-tyrosine-silk ammonia
Acid-TE-Leu-Ile-phenylalanine-tyrosine-lle-Glu-methionine-day
L-aminobutanedioic acid-proline, it has various biological function, includes the ability of regulation NF- κ B transcription factor binding purpose genes,
Influence the transcript and expression of NF- κ B target gene product albumen matter；PCNA combination archaeal dna polymerases are blocked, so as to prevent cell DNA
Synthesis suppresses cell propagation；Suppress epithelial hyperplasia, regulation epidermal hyperplasia and differentiation, make Keratoderma process normalization etc..
Inventor has found to find that N15 polypeptides can produce inhibitory action to the growth of various fungies under study for action.
Early-stage Study shows that N15 is added in yeast can play the effect for suppressing Yeast proliferation.By detecting yeast cells
Interior DNA content finds that N15 can cause the reduction of the DNA content in yeast cells, therefore the propagation of N15 suppression yeast cells can
It can be realized by suppressor group DNA replication dna.In addition, our result show that N15 polypeptides can also suppress red hair
Tinea bacterium, the propagation of Candida albicans.
It is the aqueous solution of N15 polypeptides, concentration is more than present invention also offers antifungal drug prepared by a kind of N15 polypeptides
Equal to 500 μ g/mL.
Beneficial effects of the present invention：N15 polypeptides are a kind of clear in structure, it is easy to the polypeptide of industrialized production, and it can press down
The propagation of a variety of fungies such as yeast processed, Candida albicans, Trichophyton rubrum, effect is good and has no toxic side effect.
Brief description of the drawings
Fig. 1 is Contrast on effect photos of the N15 to the Cell suppression test of saccharomyces cerevisiae.
Fig. 2 is influences of the flow cytomery N15 to saccharomyces cerevisiae DNA content.
Embodiment
Make further demonstration to the present invention with specific experiment example below in conjunction with the accompanying drawings to illustrate, following experimental example is only to this
The explanation of invention and the invention is not limited in following experimental example.
Experimental example 1：Growths of the N15 to saccharomyces cerevisiae is inhibited
Experimental method：
YEPD culture medium solid plates are prepared in the culture dish of 35mm diameters, then N15 is coated on solid plate
(N15 final concentration of 2mg/mL).The saturation saccharomyces cerevisiae bacterium solution of incubated overnight is taken, with physiological saline, doubling dilution to 10-4It is dense
Degree, takes the μ L of bacterium solution 50 to be added in solid plate, uniform with sterile glass rod coating, and 30 degree are cultivated 48 hours, observation experiment knot
Really, Fig. 1 is as a result seen.
As a result show, the circular saccharomycete single bacterium colony of visible white on flat board, neat in edge, the smooth moistening in surface.With it is right
Compared according to saccharomycete single bacterium colony, saccharomycete (B1) the single bacterium colony diameter for adding N15 polypeptides is substantially less than normal, N15 gives birth to saccharomyces cerevisiae
It is long that there is depression effect.
Experimental example 2：N15 has depression effect to the DNA replication dna of saccharomyces cerevisiae
Experimental method：
YEPD fluid nutrient mediums are prepared, saccharomyces cerevisiae is cultivated, and added in N15 to YEPD fluid nutrient mediums, are set simultaneously
The saccharomyces cerevisiae of N15 polypeptides is not added with as control (control), the cell cycle is carried out first by α factor pairs yeast cells same
Stepization processing, obtains synchronized yeast cells.N15 polypeptides (the μ g/mL of final concentration 500) are added, in processing 0 hour, 1 small
When, 2 hours, 15 hours, 15.5 hours, 16 hours separately sampled 2mL yeast thalline, add Sytox-Green dyestuffs to yeast
Cell DNA dyeing after, using flow cytometer carry out brewing yeast cell DNA relative amounts be measured, as a result see Fig. 2 and
Table 1.
Table 1.N15 is to the saccharomyces cerevisiae DNA replication dna histamine result table of comparisons (relative dna content of brewing yeast cell)
As shown in experimental result, abscissa represents the content of DNA in single yeast cells, and ordinate represents yeast count
Amount.Handled in N15 in 2 hours, the intracellular DNA content of N15 processing compares no significant difference with control cell, and with
The increase of time, after N15 is handled 15 hours, the intracellular DNA content of N15 processing is compared with control cell to be significantly reduced.
The result shows that N15 can cause the reduction of yeast cells DNA content.
Experimental example 3：Growths of the N15 to Candida albicans is inhibited
Weigh N15 polypeptide dry powders 1mg. to be dissolved in the sterile H2O of 1mL, be configured to 1mg/mL mother liquor, then with multiple proportions
Dilution method is diluted to the N15 solution of various concentrations gradient.The N15 solution of various concentrations is added drop-wise on aseptic filter paper piece to be made
N15 dosage is the drug sensitive test paper of 100,50,20,10,5,2,0.5 (unit μ g/ pieces).Candida albicans bacterium solution is applied to husky Bao Shi fine jades
On fat culture medium flat plate.The N15 drug sensitive test papers of various dose and PBS blank control drug sensitive test papers are labelled to put down and pulled, is placed in
Culture 24 hours, are measured to result in 28 DEG C of incubators.As a result it is as shown in table 2.
The inhibition zone diameter comparison sheet that the paper disk method N15 of table 2. is produced to Candida albicans
As shown in the results, in the N15 drug sensitive test papers of attenuated dosage, the N15 drug sensitive test papers of preceding 6 dose gradients are to its week
The Candida albicans enclosed generates obvious antibacterial ring size.Wherein high dose group N15 (100 μ g/ pieces) drug sensitive test paper is to Candida albicans
The inhibition zone diameter of bacterium is 15 ± 2.3mm, is reduced with the concentration of N15 polypeptides, the diameter of antibacterial ring size is also gradually reduced, and works as N15
When the dosage of polypeptide is less than 10 μ g/ pieces, do not occur obvious antibacterial ring size.
Experimental example 4：Growths of the N15 to Trichophyton rubrum is inhibited
Weigh N15 polypeptide dry powders 1mg. to be dissolved in the sterile H2O of 1mL, be configured to 1mg/mL mother liquor, then with multiple proportions
Dilution method is diluted to the N15 solution of various concentrations gradient.It will be inoculated on potato dextrose agar slant culture medium (PDA)
After Trichophyton rubrum incubated at room temperature transferred species 2 times, sterile saline rinses bacterium colony surface repeatedly, collects mycelia fragment and spore liquid
Body, scrubbed concussion, using blood cell counting plate method of counting, RPMI-1640 do dilute by suspension be modulated into (0.4~5) ×
104CFU/ml bacteria suspensions are standby.1~8 hole adds 0.1ml final concentration decoctions per hole, if negative control hole (plus bacterium solution is not added with decoction),
1.024,0.512 are obtained after blank control wells (only plus RPMI-1640 nutrient solutions), plus 0.1ml bacteria suspensions, doubling dilution,
0.256,0.128,0.064,0.032,0.016 and 0.008mg/ml 8 concentration mixed liquors, are incubated at room temperature 7 days.
According to following scale：0：Naked eyes are clear；1：Slightly obscure (80% is suppressed)；2：Turbidity significantly lowers (50%
It is suppressed)；3：Turbidity slightly lowers；4：Turbidity does not lower.This experiment takes 1 (slightly obscuring) or 2 (turbidity significantly lowers) to judge
Terminal.As a result show, N15 MIC is 500~700 μ g/ml.
The fungistatic effect of N15 polypeptides may act on a variety of fungies, and above-described embodiment is only the citing to fungistat, is chosen
More representational fungi is selected, it is impossible to the Inhibition test example of all fungal species is listed one by one, the present invention is not so limited
Scope.
Claims (5)
- Purposes of the 1.N15 polypeptides in fungistat is prepared.
- 2. purposes of the N15 polypeptides according to claim 1 in fungistat is prepared, it is characterised in that：The fungi For yeast.
- 3. purposes of the N15 polypeptides according to claim 1 in fungistat is prepared, it is characterised in that：The fungi For Candida albicans.
- 4. purposes of the N15 polypeptides according to claim 1 in fungistat is prepared, it is characterised in that：The fungi For Trichophyton rubrum.
- 5. antifungal drug prepared by a kind of N15 polypeptides, it is characterised in that：The antifungal drug is the aqueous solution of N15 polypeptides, Concentration is more than or equal to 500 μ g/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611168581.5A CN107050421A (en) | 2016-12-16 | 2016-12-16 | Purposes of the N15 polypeptides in fungistat is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611168581.5A CN107050421A (en) | 2016-12-16 | 2016-12-16 | Purposes of the N15 polypeptides in fungistat is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107050421A true CN107050421A (en) | 2017-08-18 |
Family
ID=59618605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611168581.5A Pending CN107050421A (en) | 2016-12-16 | 2016-12-16 | Purposes of the N15 polypeptides in fungistat is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107050421A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111870683A (en) * | 2020-09-17 | 2020-11-03 | 北京欣颂生物科技有限公司 | Application of antibacterial peptide in preparation of medicines or cosmetics |
| CN113368214A (en) * | 2020-07-26 | 2021-09-10 | 武汉益承生物科技有限公司 | Application of polypeptide in preparing medicine for treating wound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102321158A (en) * | 2011-08-23 | 2012-01-18 | 常州德健生物科技有限公司 | Polypeptide for preventing cell DNA synthesis and inhibiting cell proliferation and application |
| CN104043102A (en) * | 2014-03-28 | 2014-09-17 | 武汉益承生物科技股份有限公司 | Use of polypeptide in preparation of drug for treating nuclear factor-kB abnormal activation diseases |
-
2016
- 2016-12-16 CN CN201611168581.5A patent/CN107050421A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102321158A (en) * | 2011-08-23 | 2012-01-18 | 常州德健生物科技有限公司 | Polypeptide for preventing cell DNA synthesis and inhibiting cell proliferation and application |
| CN104043102A (en) * | 2014-03-28 | 2014-09-17 | 武汉益承生物科技股份有限公司 | Use of polypeptide in preparation of drug for treating nuclear factor-kB abnormal activation diseases |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368214A (en) * | 2020-07-26 | 2021-09-10 | 武汉益承生物科技有限公司 | Application of polypeptide in preparing medicine for treating wound |
| WO2022022475A1 (en) * | 2020-07-26 | 2022-02-03 | 武汉益承生物科技有限公司 | Use of polypeptide in preparation of wound treatment drug |
| CN111870683A (en) * | 2020-09-17 | 2020-11-03 | 北京欣颂生物科技有限公司 | Application of antibacterial peptide in preparation of medicines or cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mehmood et al. | Fungal quorum-sensing molecules and inhibitors with potential antifungal activity: a review | |
| Nenoff et al. | In vitro susceptibility testing of yeasts to nystatin–low minimum inhibitory concentrations suggest no indication of in vitro resistance of Candida albicans, Candida species or non-Candida yeast species to nystatin | |
| Roth Jr et al. | In vitro studies of the antifungal antibiotic griseofulvin | |
| CN107828665A (en) | A kind of isolation and purification method of purpleback murdannia herb endogenetic fungus and its application | |
| US20200368262A1 (en) | Use of Timosaponin Enzymatically Transformed Product in Preparation of Drugs for Inhibiting Skin Superficial Fungi | |
| Karwa et al. | Naturally occurring medicinal mushroom-derived antimicrobials: a case-study using Lingzhi or Reishi Ganoderma lucidum (W. Curt.: Fr.) P. Karst.(higher Basidiomycetes) | |
| CN107050421A (en) | Purposes of the N15 polypeptides in fungistat is prepared | |
| CN102293771A (en) | Medicinal composition for treating mycotic infection at superficial part and application thereof | |
| CN104031844A (en) | Cladosporium sp. strain, and extract and application thereof | |
| CN110448554B (en) | Application of D-penicillamine and fluconazole in preparation of antifungal product | |
| CN102696592A (en) | New application of pterostilbene to anti-fungal biofilm | |
| de Lima Carvalho et al. | Anti-candida activity of cinnamon inhibition of virulence factors of clinical strains of Candida albicans by essential oil of Cinnamomum zeylanicum | |
| CN103251636B (en) | Medicament for treating Candida infections and diseases caused by Candida, and preparation method thereof | |
| Kumar et al. | A study on phenotypic traits of Candida species isolated from blood stream infections and their in vitro susceptibility to fluconazole | |
| CN111905018A (en) | Preparation method and application of zanthoxylum bungeanum maxim extract | |
| CN106177035B (en) | Preparation method and application of effective rosa chinensis flower extract with blood sugar reducing and anticancer functions | |
| Rizqilah et al. | Inhibitory of soursop leaves (Annona muricata L.) extract against Malassezia furfur growth | |
| Krakhecke et al. | In vitro susceptibility testing of Microsporum gypseum isolated from healthy cattle and soil samples against itraconazole, terbinafine, fluconazole and topical veterinarian drugs | |
| CN113367166A (en) | Eugenia jambolana extract bactericide as well as preparation method and application thereof | |
| Diba et al. | In vitro activity of propolis alcoholic extract on opportunistic pathogenic fungi | |
| Guo et al. | Effect of Cinnamaldehyde on Systemic Candida albicans Infection in Mice | |
| CN108420821A (en) | A kind of antimycotic topical composition of compound | |
| CN114703064B (en) | Method for extracting ganoderma lucidum by breaking cell walls of ganoderma lucidum and breaking cell walls of ganoderma lucidum by using trichoderma harzianum | |
| CN107261146A (en) | A kind of Sodium Houttuyfonate prepares the composition for killing resistance aspergillus fumigatus and its application | |
| CN118615288A (en) | Application of chelerythrine in preparing broad-spectrum antifungal products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |
|
| RJ01 | Rejection of invention patent application after publication |